To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations

← catalyst calendar

NCT06194448

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.

Phase

Phase 2

Status

Active, not recruiting

Study type

Interventional

Design

Na · None · Treatment

Enrollment

76actual

Sites

Countries

China, Israel, South Korea +6

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-04-21

actual

When the study began enrolling

Primary completion

2026-07-07

actual

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-07-07

estimated

The whole study's end, after follow-up

First posted

2024-01-08

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-19

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Lung Cancer

Interventions

Drug: Osimertinib — also filed as Tagrisso, AZD9291
Drug: Cisplatin or Carboplatin; Pemetrexed or Paclitaxel
Drug: Radiation

Primary outcome

what the primary-completion date above is the date OF

PFS (Progression-Free Survival)

measured Assessed from date of first dose to progression (up to a maximum of approximately 4 years)

Publications

PMID 41236484 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed